A randomized clinical trial of the efficacy and safety of sitagliptin as initial oral therapy in youth with type 2 diabetes.
R Ravi ShankarPhilip S ZeitlerAsma DeebMuhammad Yazid JalaludinRaymundo GarciaRon S NewfieldYulia SamoilovaCarmen A RosarioNaim ShehadehChandan K SahaYilong ZhangMartina ZilliLynn W SchererRaymond L H LamGregory T GolmSamuel S EngelKeith D KaufmanPublished in: Pediatric diabetes (2021)
DPP-4 inhibition with sitagliptin did not provide significant improvement in glycemic control. In this study, sitagliptin was generally well tolerated with a safety profile similar to that reported in adults. (ClinicalTrials.gov: NCT01485614 EudraCT: 2011-002528-42) This article is protected by copyright. All rights reserved.